1. Search Result
Search Result
Results for "

c-Myc G4

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162294

    c-Myc Cancer
    c-Myc inhibitor 13 (compound A6) is a c-MYC transcription inhibitor. c-Myc inhibitor 13 selectively stabilizes c-MYC G4 and inhibits G4-associated c-MYC transcription .
    c-Myc inhibitor 13
  • HY-145843

    c-Myc Cancer
    c-Myc inhibitor 5 (DA3) is a fluorescent, long chain-bridged bispurine that selectively targets the c-MYC G-quadruplex (KD of 16 μM). c-Myc inhibitor 5 shows inhibition on c-MYC expression rather than other G4-driven oncogenes .
    c-Myc inhibitor 5
  • HY-147973

    c-Myc Apoptosis Cancer
    IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the c-MYC expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research .
    IZTZ-1
  • HY-174403

    Bcl-2 Family c-Myc Apoptosis Caspase Cancer
    c-MYC/BCL2 ligand 1 iodide is a dual-targeting c-MYC/Bcl-2 G4 ligand with Kd values of 0.90 μM (c-MYC G4) and 0.56 μM (Bcl-2 G4). c-MYC/BCL2 ligand 1 iodide inhibits c-MYC and Bcl-2 gene transcription by binding to G4-forming sequences and downregulates their protein expression. c-MYC/BCL2 ligand 1 iodide inhibits suppresses migration, induces caspase-dependent apoptosis, and triggers cell cycle G1 arrest in MCF-7 cells. c-MYC/BCL2 ligand 1 iodide significantly suppresses tumor growth in a 4T1 syngeneic model with no observable toxicity. c-MYC/BCL2 ligand 1 iodide can be used for the research of breast cancer.
    c-MYC/BCL2 ligand 1 iodide
  • HY-177872

    NSC 338258

    Drug Derivative c-Myc Apoptosis Cancer
    GQC-05 (NSC338258), Ellipticine (HY-15753) derivative, is potent and selective c-Myc G-quadruplex ( c-Myc G4) stabilizer with KD values of 0.1-1.43 μM. GQC-05 can reduce Myc expression and induce cancer cells apoptosis. GQC-05 can be used for the research of cancer, such as Burkitt lymphoma .
    GQC-05
  • HY-176066A

    c-Myc Apoptosis Cancer
    c-Myc inhibitor 16 iodide (Compound W11) is a selective c-Myc G-quadruplex (c-Myc G4) inhibitor. c-Myc inhibitor 16 iodide inhibits the transcription and translation of the c-Myc gene, disrupts the tumor cell cycle, arrests cell growth in the G0/G1 phase and activates the mitochondrial apoptosis pathway to induce early apoptosis of cancer cells. c-Myc inhibitor 16 iodide is promising for research of breast cancer .
    c-Myc inhibitor 16 iodide
  • HY-162796

    Apoptosis G-quadruplex c-Myc Cancer
    TS-2 is a fluorescent ligand of c-Myc G4 with anticancer activity. TS-2 inhibits the growth of cancer cells and induces apoptosis of cancer cells by targeting the c-MYC oncogene promoter G4, causing transcriptional repression of the c-Myc oncogene .
    TS-2
  • HY-151471

    c-Myc Cancer
    Anticancer agent 84 is an anticancer agent. Anticancer agent 84 represses the transcription of c-MYC by stabilizing the G-quadruplex (G4) structure. Anticancer agent 84 can be used for the research of cancer .
    Anticancer agent 84
  • HY-149513

    c-Myc Apoptosis Cancer
    EP12 is a c-Myc inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .
    EP12
  • HY-168886

    c-Myc Cancer
    Anticancer agent 263 (compound 7) is a potent anticancer agent. Anticancer agent 263 binds to the G-quadruplex DNA (G4) sequence 22-mer Pu22, a mimic of c-Myc DNA. Anticancer agent 263 is a structure modulator, showcasing a significant enhancement in protein α-helix formation and the capability to form supramolecular network. Anticancer agent 263 shows no cytotoxicity .
    Anticancer agent 263
  • HY-181234

    c-Myc Apoptosis Cancer
    Y502-3888 is a c-Myc inhibitor. Y502-3888 binds to the c-Myc G4 structure, inhibits c-Myc transcription, and downregulates c-Myc expression at both mRNA and protein levels. Y502-3888 inhibits the viability of myeloma cells and induces cell apoptosis. Y502-3888 can be used for the research of multiple myeloma .
    Y502-3888
  • HY-182055

    G-quadruplex Keap1-Nrf2 Ferroptosis Apoptosis Cancer
    Anticancer agent 309 (Compound HZ-1) is an anticancer agent and G-quadruplex binder, with Kd values of 2.46 μM and 1.61 μM for c-Myc G4 and KRAS G4, respectively. Anticancer agent 309 promotes the formation of intranuclear G4. Anticancer agent 309 shows higher selectivity for parallel G4 than for non-parallel G4. Anticancer agent 309 inhibits the NRF2 signaling pathway and reduces the expression of XCT and GPX4. Anticancer agent 309 induces Ferroptosis, Apoptosis and immunogenic cell death in cells. Anticancer agent 309 exerts antitumor efficacy against breast cancer. Anticancer agent 309 is applicable for the research of breast cancer .
    Anticancer agent 309
  • HY-182029

    G-quadruplex Cancer
    G-quadruplex ligand 5 is a G-quadruplex (G4) ligand. G-quadruplex ligand 5 selectively stabilizes cancer-associated G4 oligonucleotides and shows cytotoxicity toward cancer cells. G-quadruplex ligand 5 can be used for the research of cancer .
    G-quadruplex ligand 5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: